Abstract
Twenty-nine children (23 girls, 6 boys) with precocious puberty were treated with cyproterone acetate for various periods of time ranging from 6 months to 3 years 4 months. They received an oral dose ranging from 70-150 mg/m2 per day, or an intramuscular depot injection once a fortnight or once a month at a dose ranging from 107-230 mg/m2. Both forms of therapy were found to suppress the signs of sexual maturation, but the oral form proved to be superior. Only the younger patients with a bone age under 11 years showed a beneficial effect upon linear growth and bone maturation. No side effects were noted, but additional advantageous effects upon behaviour and sociability were. It is concluded that at present cyproterone acetate by mouth is the drug of choice in the treatment of precocious puberty. The treatment should be initiated as early as possible to attain maximum benefit.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- ALBERT A. Procedure for routine clinical determination of urinary gonadotropin. Proc Staff Meet Mayo Clin. 1955 Nov 16;30(23):552–556. [PubMed] [Google Scholar]
- Bossi E., Zurbrügg R. P., Joss E. E. Improvement of adult height prognosis in precocious puberty by cyproterone acetate. Acta Paediatr Scand. 1973 Jul;62(4):405–412. doi: 10.1111/j.1651-2227.1973.tb08128.x. [DOI] [PubMed] [Google Scholar]
- Cloutier M. D., Hayles A. B. Precocious puberty. Adv Pediatr. 1970;17:125–138. [PubMed] [Google Scholar]
- David M., Bovier-Lapierre M., Sempé M. Le traitement des pubertés précoces par l'acétate de médroxyprogestérone. Pediatrie. 1972 Sep;27(6):623–645. [PubMed] [Google Scholar]
- Greenblatt R. B., Dmowski W. P., Mahesh V. B., Scholer H. F. Clinical studies with an antigonadotropin-Danazol. Fertil Steril. 1971 Feb;22(2):102–112. doi: 10.1016/s0015-0282(16)38045-1. [DOI] [PubMed] [Google Scholar]
- HAHN H. B., Jr, HAYLES A. B., ALBERT A. MEDROXYPROGESTERONE AND CONSTITUTIONAL PRECOCIOUS PUBERTY. Mayo Clin Proc. 1964 Mar;39:182–190. [PubMed] [Google Scholar]
- Johnson D. C., Naqvi R. H. Effect of cyproterone acetate on LH in immature rats. Endocrinology. 1969 Feb;84(2):421–425. doi: 10.1210/endo-84-2-421. [DOI] [PubMed] [Google Scholar]
- Kaplan S. A., Ling S. M., Irani N. G. Idiopathic isosexual precocity. Am J Dis Child. 1968 Dec;116(6):591–598. doi: 10.1001/archpedi.1968.02100020595004. [DOI] [PubMed] [Google Scholar]
- Kauli R., Prager-Lewin R., Keret R., Laron Z. The LH response to LH releasing hormone in children with true isosexual precocious puberty treated with cyproterone acetate. Clin Endocrinol (Oxf) 1975 May;4(3):305–311. doi: 10.1111/j.1365-2265.1975.tb01538.x. [DOI] [PubMed] [Google Scholar]
- Midgley A. R., Jr Radioimmunoassay: a method for human chorionic gonadotropin and human luteinizing hormone. Endocrinology. 1966 Jul;79(1):10–18. doi: 10.1210/endo-79-1-10. [DOI] [PubMed] [Google Scholar]
- Prader A. Testicular size: assessment and clinical importance. Triangle. 1966;7(6):240–243. [PubMed] [Google Scholar]
- Rager K., Huenges R., Gupta D., Bierich J. R. The treatment of precocious puberty with cyproterone acetate. Acta Endocrinol (Copenh) 1973 Oct;74(2):399–408. doi: 10.1530/acta.0.0740399. [DOI] [PubMed] [Google Scholar]
- Werder E. A., Mürset G., Zachmann M., Brook C. G., Prader A. Treatment of precocious puberty with cyproterone acetate. Pediatr Res. 1974 Apr;8(4):248–256. doi: 10.1203/00006450-197404000-00006. [DOI] [PubMed] [Google Scholar]
- Zilka E., Laron Z. [The normal testicular volume in Israeli children and adolescents]. Harefuah. 1969 Dec 1;77(11):511–513. [PubMed] [Google Scholar]